NMTC Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2026Q2

-0.040

-166.67%

-0.045

-35.71%

Estimates Revision

The market is revising No Change the revenue expectations for NeuroOne Medical Technologies Corporation (NMTC) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -7.79%.

Revenue Estimates for FY2026

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2026

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-7.79%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast NMTC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NMTC is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

3.00

Averages

3.00

High

3.00

Current: 0.000

Low

3.00

Averages

3.00

High

3.00

Maxim

initiated

2025-09-09

Reason

Maxim

Price Target

2025-09-09

initiated

Reason

Maxim initiated coverage of NeuroOne Medical with a Buy rating and $3 price target.

Valuation Metrics

The current forward P/E ratio for NeuroOne Medical Technologies Corp (NMTC.O) is -5.50, compared to its 5-year average forward P/E of -3.41. For a more detailed relative valuation and DCF analysis to assess NeuroOne Medical Technologies Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.41

Current PE

-5.50

Overvalued PE

-1.63

Undervalued PE

-5.19

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.96

Current EV/EBITDA

-3.94

Overvalued EV/EBITDA

0.01

Undervalued EV/EBITDA

-1.93

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

98.05

Current PS

3.82

Overvalued PS

323.73

Undervalued PS

-127.62

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

NMTC News & Events

Events Timeline

No data

News

2.0

2025-10-07NASDAQ.COM

TELO, PCSA, RVPH, NMTC, BRTX Experience After-Hours Trading Surge Amid Limited News and Specific Updates

2.0

2025-10-01NASDAQ.COM

Biotech Stocks Recover in After-Hours Trading Driven by Positive Sector Trends

9.0

2025-08-18Newsfilter

NeuroOne® Obtains FDA 510(k) Approval for OneRF® Trigeminal Nerve Ablation System to Address Facial Pain

People Also Watch

Frequently Asked Questions

What is NeuroOne Medical Technologies Corp (NMTC) stock price today?

The current price of NMTC is 0.876 USD — it has decreased -1.79 % in the last trading day.

What is NeuroOne Medical Technologies Corp (NMTC)'s business?

NeuroOne Medical Technologies Corporation is a medical technology company. It is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. It may also pursue applications for other areas such as depression, mood disorders, incontinence and artificial intelligence. Its products include Evo cortical electrode technology for recording, monitoring, and stimulating brain tissue for up to 30 days; Evo sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain, and OneRF ablation system for creation of radiofrequency lesions in nervous tissue for functional neurosurgical procedures.

What is the price predicton of NMTC Stock?

What is NeuroOne Medical Technologies Corp (NMTC)'s revenue for the last quarter?

NeuroOne Medical Technologies Corp revenue for the last quarter amounts to 2.74M USD, increased 906.64 % YoY.

What is NeuroOne Medical Technologies Corp (NMTC)'s earnings per share (EPS) for the last quarter?

NeuroOne Medical Technologies Corp. EPS for the last quarter amounts to -0.03 USD, decreased -72.73 % YoY.

What changes have occurred in the market's expectations for NeuroOne Medical Technologies Corp (NMTC)'s fundamentals?

How many employees does NeuroOne Medical Technologies Corp (NMTC). have?

NeuroOne Medical Technologies Corp (NMTC) has 18 emplpoyees as of January 10 2026.

What is NeuroOne Medical Technologies Corp (NMTC) market cap?

Today NMTC has the market capitalization of 44.16M USD.